Literature DB >> 968459

Interaction between cephaloridine and furosemide in man.

R Norrby, K Stenqvist, B Elgefors.   

Abstract

The effect of a moderate oral dose of furosemide (80 mg daily) on the serum half-life of cephaloridine was studied. In 14 patients not previously treated with diuretics this dose was found to prolong the half-life significantly. A corresponding decrease of the half-life of cephaloridine was observed when furosemide was withdrawn from 2 patients who were treated with diuretics at admission to hospital. The concurrent treatment with furosemide and cephaloridine did not affect the renal function of the patients studied. From the results obtained it seems possible that even moderate doses of a potent diuretic increase the nephrotoxicity of a cephalosporin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 968459     DOI: 10.3109/inf.1976.8.issue-3.17

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  6 in total

Review 1.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 2.  Side effects of cephalosporins.

Authors:  S R Norrby
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter.

Authors:  Lei Diao; Sean Ekins; James E Polli
Journal:  Mol Pharm       Date:  2010-09-29       Impact factor: 4.939

4.  Effects of furosemide, piretanide, and water loading on urinary excretion of cefazolin in humans.

Authors:  C Morgant; A Contrepois; N P Chau; A Romaru; J B Fourtillan; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

5.  Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency.

Authors:  R A Walstad; O G Nilsen; K J Berg
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 6.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.